| Abstract P251 – Table 1. Baseline characteristics of 59 PLWHIV and anti‐SARS‐CoV‐2 IgG antibodies levels, 3 months after two doses of AZD1222 (ChAdOx1). Values are frequencies or median with percentages or first to third quartiles in parenthesis. | ||||
|---|---|---|---|---|
| Antibody levels after 3 months | ||||
| <1000 AU/mL (N = 40) | ≥1000 AU/mL (N = 19) | Total (N = 59) | p‐value | |
| Male gender | 38 (95.0) | 19 (100.0) | 57 (96.6) | >0.99 |
| Age, years | 43.5 (38.7 to 52.2) | 46.2 (40.3 to 51.2) | 45.0 (39.0 to 51.6) | 0.73 |
| Age >50 years | 14 (35.0) | 5 (26.3) | 19 (32.2) | 0.50 |
| Transmission | >0.99 | |||
| Heterosexual | 2 (5.0) | 1 (5.3) | 3 (5.1) | |
| MSM | 38 (95.0) | 18 (94.7) | 56 (94.9) | |
| Duration of HIV infection, years | 6.1 (3.2 to 8.9) | 7.9 (4.3 to 11.9) | 6.1 (3.5 to 10.6) | 0.36 |
| Had clinical AIDS | 8 (20.0) | 1 (5.3) | 9 (15.3) | 0.14 |
| CD4 cell count, per mm3 | 760.0 (570.5 to 873.0) | 697.0 (452.0 to 962.0) | 722.0 (520.0 to 878.0) | 0.46 |
| CD4 cell count, >800 per mm3 | 16 (40.0) | 7 (36.8) | 23 (39.0) | 0.82 |
| Nadir CD4 cell count, per mm3 | 290.0 (109.0 to 398.5) | 292.0 (139.0 to 424.0) | 292.0 (130.0 to 408.0) | 0.82 |
| CD4/CD8 ratio | 0.9 (0.7 to 1.2) | 0.9 (0.7 to 1.1) | 0.9 (0.7 to 1.2) | 0.83 |
| BMI, kg/m2 | 26.0 (23.2 to 27.6) | 27.0 (25.4 to 28.4) | 26.2 (23.5 to 27.7) | 0.15 |
| BMI categories, kg/m2 | 0.52 | |||
| <18.5 | 1 (2.5) | 0 (0.0) | 1 (1.7) | |
| 18.5 to 24.9 | 15 (37.5) | 4 (21.1) | 19 (32.2) | |
| 25.0 to 29.9 | 19 (47.5) | 12 (63.2) | 31 (52.5) | |
| ≥30 | 5 (12.5) | 3 (15.8) | 8 (13.6) | |
| Antiretroviral therapy | 0.29 | |||
| 1NRTI+INSTI | 12 (30.0) | 5 (26.3) | 17 (28.8) | |
| 2NRTI+INSTI | 13 (32.5) | 10 (52.6) | 23 (39.0) | |
| 2NRTI+NRTI | 15 (37.5) | 4 (21.1) | 19 (32.2) | |
BMI, body mass index; INSTI, integrase inhibitors; NRTI, nucleoside reverse transcriptase inhibitors; NNRTI, non‐nucloside reverse transcriptase inhibitors.